Literature DB >> 10527889

A crucial role of caspase 3 and caspase 8 in paclitaxel-induced apoptosis.

H Oyaizu1, Y Adachi, S Taketani, R Tokunaga, S Fukuhara, S Ikehara.   

Abstract

The anticancer drug paclitaxel is well known as an inhibitor of microtubule depolymerization, resulting in mitosis arrest. We investigated the mechanism underlying antitumor effects of paclitaxel on the lung adenocarcinoma cell line LC-2-AD. Less than 10 microg/ml paclitaxel induced mitosis arrest upon LC-2-AD, followed by apoptosis, but more than 30 microg/ml paclitaxel induced apoptosis without mitosis arrest. LC-2-AD with less than 1 microg/ml paclitaxel showed a loss of mitochondrial transmembrane potential (deltapsim), which correlated with antitumor effects. However, LC-2-AD with more than 10 microg/ml paclitaxel showed slight changes in the loss of deltapsim in spite of its ability to induce apoptosis significantly. The cleavage of caspase 3, caspase 8, and DFF45/ICAD was also observed in paclitaxel-induced apoptosis, and the inhibitor of caspase 3 and caspase 8 inhibited both antitumor effects and apoptosis induced by paclitaxel. These results suggest that activation of caspase 3 and caspase 8 plays a crucial role in paclitaxel-induced apoptosis under any concentrations of paclitaxel.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10527889     DOI: 10.1006/mcbr.1999.0146

Source DB:  PubMed          Journal:  Mol Cell Biol Res Commun        ISSN: 1522-4724


  10 in total

1.  Nanoparticle Design Strategies for Effective Cancer Immunotherapy.

Authors:  Praveena Velpurisiva; Aniket Gad; Brandon Piel; Rahul Jadia; Prakash Rai
Journal:  J Biomed (Syd)       Date:  2017

2.  Identification of a novel synthetic thiazolidin compound capable of inducing c-Jun NH2-terminal kinase-dependent apoptosis in human colon cancer cells.

Authors:  Fuminori Teraishi; Shuhong Wu; Lidong Zhang; Wei Guo; John J Davis; Fengqin Dong; Bingliang Fang
Journal:  Cancer Res       Date:  2005-07-15       Impact factor: 12.701

3.  Caspase-mediated specific cleavage of BubR1 is a determinant of mitotic progression.

Authors:  Mijin Kim; Katie Murphy; Fang Liu; Sharon E Parker; Melissa L Dowling; Wesley Baff; Gary D Kao
Journal:  Mol Cell Biol       Date:  2005-11       Impact factor: 4.272

4.  Combined-modality radioimmunotherapy: synergistic effect of paclitaxel and additive effect of bevacizumab.

Authors:  Beom-Su Jang; Sang-Myung Lee; Hyung Sub Kim; In Soo Shin; Faezeh Razjouyan; Shutao Wang; Zhengsheng Yao; Ira Pastan; Matthew R Dreher; Chang H Paik
Journal:  Nucl Med Biol       Date:  2011-12-14       Impact factor: 2.408

5.  The microtubule-targeting agent CA4P regresses leukemic xenografts by disrupting interaction with vascular cells and mitochondrial-dependent cell death.

Authors:  Isabelle Petit; Matthias A Karajannis; Loic Vincent; Lauren Young; Jason Butler; Andrea T Hooper; Koji Shido; Hermann Steller; David J Chaplin; Eric Feldman; Shahin Rafii
Journal:  Blood       Date:  2007-11-16       Impact factor: 22.113

6.  Reporter nanoparticle that monitors its anticancer efficacy in real time.

Authors:  Ashish Kulkarni; Poornima Rao; Siva Natarajan; Aaron Goldman; Venkata S Sabbisetti; Yashika Khater; Navya Korimerla; Vineethkrishna Chandrasekar; Raghunath A Mashelkar; Shiladitya Sengupta
Journal:  Proc Natl Acad Sci U S A       Date:  2016-03-29       Impact factor: 11.205

7.  EF24 induces G2/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by increasing PTEN expression.

Authors:  Karuppaiyah Selvendiran; Liyue Tong; Shilpa Vishwanath; Anna Bratasz; Nancy J Trigg; Vijay K Kutala; Kalman Hideg; Periannan Kuppusamy
Journal:  J Biol Chem       Date:  2007-08-07       Impact factor: 5.157

8.  Human beta-galactoside alpha-2,3-sialyltransferase (ST3Gal III) attenuated Taxol-induced apoptosis in ovarian cancer cells by downregulating caspase-8 activity.

Authors:  Su Huang; Travis W Day; Mi-Ran Choi; Ahmad R Safa
Journal:  Mol Cell Biochem       Date:  2009-05-05       Impact factor: 3.396

9.  Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients.

Authors:  Jürgen Sonnemann; Jennifer Gänge; Sabine Pilz; Christine Stötzer; Ralf Ohlinger; Antje Belau; Gerd Lorenz; James F Beck
Journal:  BMC Cancer       Date:  2006-07-11       Impact factor: 4.430

10.  Targeting tumor-associated carbohydrate antigens: a phase I study of a carbohydrate mimetic-peptide vaccine in stage IV breast cancer subjects.

Authors:  Laura F Hutchins; Issam Makhoul; Peter D Emanuel; Angela Pennisi; Eric R Siegel; Fariba Jousheghany; Xueyan Guo; Anastas D Pashov; Behjatolah Monzavi-Karbassi; Thomas Kieber-Emmons
Journal:  Oncotarget       Date:  2017-10-23
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.